Cargando…
FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prog...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288160/ https://www.ncbi.nlm.nih.gov/pubmed/27224915 http://dx.doi.org/10.18632/oncotarget.9507 |
_version_ | 1782504277711781888 |
---|---|
author | Wong, Kah Keng Gascoyne, Duncan M. Soilleux, Elizabeth J. Lyne, Linden Spearman, Hayley Roncador, Giovanna Pedersen, Lars M. Møller, Michael B. Green, Tina M. Banham, Alison H. |
author_facet | Wong, Kah Keng Gascoyne, Duncan M. Soilleux, Elizabeth J. Lyne, Linden Spearman, Hayley Roncador, Giovanna Pedersen, Lars M. Møller, Michael B. Green, Tina M. Banham, Alison H. |
author_sort | Wong, Kah Keng |
collection | PubMed |
description | FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell (ABC)-like subtype display partially blocked plasma cell differentiation. FOXP2 protein expression was detected in ABC-DLBCL cell lines, and in primary DLBCL samples tumoral FOXP2 protein expression was detected in both germinal center B-cell-like (GCB) and non-GCB DLBCL. In biopsies from DLBCL patients treated with immunochemotherapy (R-CHOP), ≥ 20% nuclear tumoral FOXP2-positivity (n = 24/158) correlated with significantly inferior overall survival (OS: P = 0.0017) and progression-free survival (PFS: P = 0.0096). This remained significant in multivariate analysis against either the international prognostic index score or the non-GCB DLBCL phenotype (P < 0.05 for both OS and PFS). Expression of BLIMP1, a marker of plasmacytic differentiation that is commonly inactivated in ABC-DLBCL, did not correlate with patient outcome or FOXP2 expression in this series. Increased frequency of FOXP2 expression significantly correlated with FOXP1-positivity (P = 0.0187), and FOXP1 co-immunoprecipitated FOXP2 from ABC-DLBCL cells indicating that these proteins can co-localize in a multi-protein complex. FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348), which is directly repressed by FOXP1, and exhibited distinct patterns of gene expression. Specifically in ABC-DLBCL these were associated with lower expression of immune response and T-cell receptor signaling pathways. Further studies are warranted to investigate the potential functional cooperativity between FOXP1 and FOXP2 in repressing immune responses during the pathogenesis of high-risk DLBCL. |
format | Online Article Text |
id | pubmed-5288160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-52881602017-02-07 FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures Wong, Kah Keng Gascoyne, Duncan M. Soilleux, Elizabeth J. Lyne, Linden Spearman, Hayley Roncador, Giovanna Pedersen, Lars M. Møller, Michael B. Green, Tina M. Banham, Alison H. Oncotarget Research Paper FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell (ABC)-like subtype display partially blocked plasma cell differentiation. FOXP2 protein expression was detected in ABC-DLBCL cell lines, and in primary DLBCL samples tumoral FOXP2 protein expression was detected in both germinal center B-cell-like (GCB) and non-GCB DLBCL. In biopsies from DLBCL patients treated with immunochemotherapy (R-CHOP), ≥ 20% nuclear tumoral FOXP2-positivity (n = 24/158) correlated with significantly inferior overall survival (OS: P = 0.0017) and progression-free survival (PFS: P = 0.0096). This remained significant in multivariate analysis against either the international prognostic index score or the non-GCB DLBCL phenotype (P < 0.05 for both OS and PFS). Expression of BLIMP1, a marker of plasmacytic differentiation that is commonly inactivated in ABC-DLBCL, did not correlate with patient outcome or FOXP2 expression in this series. Increased frequency of FOXP2 expression significantly correlated with FOXP1-positivity (P = 0.0187), and FOXP1 co-immunoprecipitated FOXP2 from ABC-DLBCL cells indicating that these proteins can co-localize in a multi-protein complex. FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348), which is directly repressed by FOXP1, and exhibited distinct patterns of gene expression. Specifically in ABC-DLBCL these were associated with lower expression of immune response and T-cell receptor signaling pathways. Further studies are warranted to investigate the potential functional cooperativity between FOXP1 and FOXP2 in repressing immune responses during the pathogenesis of high-risk DLBCL. Impact Journals LLC 2016-05-20 /pmc/articles/PMC5288160/ /pubmed/27224915 http://dx.doi.org/10.18632/oncotarget.9507 Text en Copyright: © 2016 Wong et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Wong, Kah Keng Gascoyne, Duncan M. Soilleux, Elizabeth J. Lyne, Linden Spearman, Hayley Roncador, Giovanna Pedersen, Lars M. Møller, Michael B. Green, Tina M. Banham, Alison H. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures |
title | FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures |
title_full | FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures |
title_fullStr | FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures |
title_full_unstemmed | FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures |
title_short | FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures |
title_sort | foxp2-positive diffuse large b-cell lymphomas exhibit a poor response to r-chop therapy and distinct biological signatures |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288160/ https://www.ncbi.nlm.nih.gov/pubmed/27224915 http://dx.doi.org/10.18632/oncotarget.9507 |
work_keys_str_mv | AT wongkahkeng foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT gascoyneduncanm foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT soilleuxelizabethj foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT lynelinden foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT spearmanhayley foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT roncadorgiovanna foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT pedersenlarsm foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT møllermichaelb foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT greentinam foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures AT banhamalisonh foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures |